title: Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol.
abstract: OBJECTIVE
  The efficacy and adverse effects of carbamazepine and haloperidol were compared in the treatment of inhalant-induced psychotic disorder.
  
  
  METHODS
  Forty male patients admitted to an acute psychiatric unit for treatment of inhalant dependence and inhalant-induced organic mental disorder, as diagnosed by DSM-III-R, were randomly assigned to receive five weeks of treatment with carbamazepine or haloperidol in identical-appearing capsules. The Brief Psychiatric Rating Scale and the DiMascio Extrapyramidal Symptoms Scale were administered weekly.
  
  
  RESULTS
  Both treatment groups improved significantly over time. A reduction of symptom severity of 48.3 percent in the carbamazepine group and 52.7 percent in the haloperidol group was observed. Approximately half the patients in each group were considered treatment responders at the end of the study. Adverse effects were significantly more common and more severe in the haloperidol group.
  
  
  CONCLUSIONS
  Carbamazepine appears to have comparable efficacy but fewer adverse effects than haloperidol for the treatment of inhalant-induced psychotic disorder.
authors.affiliation: Division of Clinical Research, Mexican Institute of Psychiatry in Huipulco Tlalpan, Mexico City. hernand@psychiatry.uchc.edu
authors.forename: C A
authors.initials: CA
authors.lastname: Hernandez-Avila
authors.forename: H A
authors.initials: HA
authors.lastname: Ortega-Soto
authors.forename: A
authors.initials: A
authors.lastname: Jasso
authors.forename: C A
authors.initials: CA
authors.lastname: Hasfura-Buenaga
authors.forename: H R
authors.initials: HR
authors.lastname: Kranzler
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009460:Neurologic Examination / Q000187:drug effects; D011569:Psychiatric Status Rating Scales; D011605:Psychoses, Substance-Induced / Q000534:rehabilitation*; D016320:Substance Abuse Treatment Centers; D019966:Substance-Related Disorders / Q000534:rehabilitation*; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D002220:Carbamazepine; D006220:Haloperidol